• Vera Therapeutics reported that in the second quarter of 2026 its net loss widened to US$109.47 million, with basic and diluted loss per share from continuing operations rising to US$1.52, while first-half 2026 net loss reached US$230.51 million and loss per share climbed to US$3.22.
• The company also secured accelerated FDA approval and began the commercial launch of TRUTAKNA for adults with primary IgA nephropathy, marking the first therapy to inhibit both BAFF and APRIL in this disease and setting up earlier-than-expected efficacy analysis to support a potential full approval filing.
• We’ll now examine how TRUTAKNA’s accelerated FDA approval and launch may shape Vera Therapeutics’ investment narrative despite recent share price declines.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

What Is Vera Therapeutics' Investment Narrative?

For Vera Therapeutics, being a shareholder largely comes down to believing that TRUTAKNA can evolve from an accelerated approval in a rare kidney disease into a durable, commercially meaningful franchise, while the company manages sizeable losses along the way. The recent FDA green light and launch are now the key short term catalysts, especially with the earlier final efficacy readout from ORIGIN 3 and a potential full approval filing on the horizon. At the same time, the widening net loss of US$230.51 million in the first half of 2026 underlines that Vera is still a zero-revenue, cash-consuming business, so uptake of TRUTAKNA and the strength of payer access will matter more than ever. Recent share price weakness suggests the market is still weighing these twin forces of clinical progress and financial strain.

However, investors also need to be aware of how dependent Vera now is on TRUTAKNA’s next clinical milestones. Despite retreating, Vera Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates span from about US$53.72 to a very large US$537.15, underlining how far apart views are. When you set that against Vera’s deep current losses and the importance of TRUTAKNA’s upcoming efficacy data, it highlights why performance could end up looking very different depending on how those milestones play out.

Explore 3 other fair value estimates on Vera Therapeutics - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Vera Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Vera Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vera Therapeutics' overall financial health at a glance.

No Opportunity In Vera Therapeutics?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.